Skip to main content
Top
Published in: Journal of Neurology 3/2016

01-03-2016 | Original Communication

Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors

Authors: Maria Laura Ester Bianchi, Emanuele Leoncini, Marcella Masciullo, Anna Modoni, Shahinaz M. Gadalla, Roberto Massa, Emanuele Rastelli, Chiara Terracciano, Giovanni Antonini, Elisabetta Bucci, Antonio Petrucci, Sandro Costanzi, Massimo Santoro, Stefania Boccia, Gabriella Silvestri

Published in: Journal of Neurology | Issue 3/2016

Login to get access

Abstract

Recent studies documented an increased risk of neoplasm in patients with myotonic dystrophies (DM). Yet, none of these studies evaluated the contribution of common cancer risk factors in such observation. In this study, we included a cohort of patients (n = 255) with an established molecular diagnosis of DM type 1 (DM1), and who receives their treatment in one of the four centers with recognized expertise in neuromuscular disorders in Rome. We estimated the prevalence of benign and malignant tumors, and assessed if lifestyle factors and/or specific disease features would be associated to their occurrence. Overall, 59 benign tumors in 54 patients and 19 malignant tumors in 17 patients were diagnosed. The most common malignant neoplasms were cancers of the skin (31.6 %), thyroid (21.0 %), ovary (10.5 %), and breast (10.5 %). Uterine fibroid was the most common benign tumor (37.6 %) in women, while pilomatricoma was the most common in men (28.6 %). Age at enrollment (OR = 1.02, 95 % CI 1.00–1.05), and female gender (OR = 5.71, 95 % CI 2.90–11.22) were associated with tumor development in DM1 patients, while thyroid disorders was associated with malignant tumors only in women (OR = 5.12, 95 % CI 1.35–19.37). There was no association between tumor development and evaluated lifestyle factors. In conclusion, the lack of association between common cancer risk factors and tumor development in DM1 support a pathogenic link between tumors and DM1 itself, emphasizing the need for a systematic surveillance. Our observation of an association between thyroid diseases in women and cancer development needs confirmation.
Literature
1.
2.
go back to reference PS Harper (2001) Myotonic Dystrophy, 3rd edn. London PS Harper (2001) Myotonic Dystrophy, 3rd edn. London
3.
go back to reference Cantwell AR Jr, Reed WB (1965) Myotonia atrophica and multiple calcifying epithelioma of Malherbe. Acta Derm Venereol 45:387–390PubMed Cantwell AR Jr, Reed WB (1965) Myotonia atrophica and multiple calcifying epithelioma of Malherbe. Acta Derm Venereol 45:387–390PubMed
4.
go back to reference Street ML, Rogers RS 3rd (1991) Multiple pilomatricomas and myotonic dystrophy. J Dermatol Surg Oncol 17:728–730CrossRefPubMed Street ML, Rogers RS 3rd (1991) Multiple pilomatricomas and myotonic dystrophy. J Dermatol Surg Oncol 17:728–730CrossRefPubMed
5.
go back to reference Laredo Ortiz C, Munoz Romero F, Mallent Anon J, Domenech Miro E, Tafalla Pena M (1997) Multiple pilomatrixomas associated with Steinert disease. An Med Interna 14:409–411PubMed Laredo Ortiz C, Munoz Romero F, Mallent Anon J, Domenech Miro E, Tafalla Pena M (1997) Multiple pilomatrixomas associated with Steinert disease. An Med Interna 14:409–411PubMed
6.
go back to reference Barberio E, Nino M, Dente V, Delfino M (2002) Guess what! Multiple pilomatricomas and Steiner disease. Eur J Dermatol 12:293–294PubMed Barberio E, Nino M, Dente V, Delfino M (2002) Guess what! Multiple pilomatricomas and Steiner disease. Eur J Dermatol 12:293–294PubMed
7.
go back to reference Gadalla SM, Lund M, Pfeiffer RM, Gørtz S, Mueller CM, Moxley RT 3rd, Kristinsson SY, Björkholm M, Shebl FM, Hilbert JE, Landgren O, Wohlfahrt J, Melbye M, Greene MH (2011) Cancer risk among patients with myotonic muscular dystrophy. JAMA 306:2480–2486CrossRefPubMedPubMedCentral Gadalla SM, Lund M, Pfeiffer RM, Gørtz S, Mueller CM, Moxley RT 3rd, Kristinsson SY, Björkholm M, Shebl FM, Hilbert JE, Landgren O, Wohlfahrt J, Melbye M, Greene MH (2011) Cancer risk among patients with myotonic muscular dystrophy. JAMA 306:2480–2486CrossRefPubMedPubMedCentral
9.
go back to reference Mohamed S, Pruna L, Kaminsky P (2013) Increasing risk of tumors in myotonic dystrophy type 1. Presse Med 42:281–284CrossRef Mohamed S, Pruna L, Kaminsky P (2013) Increasing risk of tumors in myotonic dystrophy type 1. Presse Med 42:281–284CrossRef
10.
go back to reference Das M, Moxley RT 3rd, Hilbert JE, Martens WB, Letren L, Greene MH, Gadalla SM (2012) Correlates of tumor development in patients with myotonic dystrophy. J Neurol 259:2161–2166CrossRefPubMedPubMedCentral Das M, Moxley RT 3rd, Hilbert JE, Martens WB, Letren L, Greene MH, Gadalla SM (2012) Correlates of tumor development in patients with myotonic dystrophy. J Neurol 259:2161–2166CrossRefPubMedPubMedCentral
11.
go back to reference Gennarelli M, Pavoni M, Amicucci P, Novelli G, Dallapiccola B (1998) A single polymerase chain reaction-based protocol for detecting normal and expanded alleles in myotonic dystrophy. Diagn Mol Pathol 7:135–137CrossRefPubMed Gennarelli M, Pavoni M, Amicucci P, Novelli G, Dallapiccola B (1998) A single polymerase chain reaction-based protocol for detecting normal and expanded alleles in myotonic dystrophy. Diagn Mol Pathol 7:135–137CrossRefPubMed
12.
go back to reference Modoni A, Silvestri G, Pomponi MG, Mangiola F, Tonali PA, Marra C (2004) Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 61:1943–1947PubMed Modoni A, Silvestri G, Pomponi MG, Mangiola F, Tonali PA, Marra C (2004) Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 61:1943–1947PubMed
13.
go back to reference [No authors listed] New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC) (2000) Neurology 54:1218-21 [No authors listed] New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC) (2000) Neurology 54:1218-21
14.
go back to reference AIRTUM Working group (2011) Italian cancer figures, report 2011: survival of cancer patients in Italy. Epidemiol Prev 35:1–200 AIRTUM Working group (2011) Italian cancer figures, report 2011: survival of cancer patients in Italy. Epidemiol Prev 35:1–200
15.
go back to reference Gadalla SM, Pfeiffer RM, Kristinsson SY, Björkholm M, Hilbert JE, Moxley RT 3rd, Landgren O, Greene MH (2013) Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis. PLoS ONE 8:e79851CrossRefPubMedPubMedCentral Gadalla SM, Pfeiffer RM, Kristinsson SY, Björkholm M, Hilbert JE, Moxley RT 3rd, Landgren O, Greene MH (2013) Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis. PLoS ONE 8:e79851CrossRefPubMedPubMedCentral
16.
go back to reference Okolo S (2008) Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 22:571–588CrossRefPubMed Okolo S (2008) Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol 22:571–588CrossRefPubMed
17.
go back to reference Lund M, Diaz LJ, Gørtz S, Feenstra B, Duno M, Juncker I, Eiberg H, Vissing J, Wohlfahrt J, Melbye M (2014) Risk of cancer in relatives of patients with myotonic dystrophy: a population-based cohort study. Eur J Neurol 21:1192–1197CrossRefPubMed Lund M, Diaz LJ, Gørtz S, Feenstra B, Duno M, Juncker I, Eiberg H, Vissing J, Wohlfahrt J, Melbye M (2014) Risk of cancer in relatives of patients with myotonic dystrophy: a population-based cohort study. Eur J Neurol 21:1192–1197CrossRefPubMed
18.
go back to reference Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11:891–905CrossRefPubMed Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11:891–905CrossRefPubMed
20.
go back to reference Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT 3rd, Greene MH (2009) Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control 20:2009–2020CrossRefPubMedPubMedCentral Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT 3rd, Greene MH (2009) Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control 20:2009–2020CrossRefPubMedPubMedCentral
21.
go back to reference Santoro M, Masciullo M, Bonvissuto D, Bianchi ML, Michetti F, Silvestri G (2013) Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2. Mol Cell Biochem 380:259–265CrossRefPubMed Santoro M, Masciullo M, Bonvissuto D, Bianchi ML, Michetti F, Silvestri G (2013) Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2. Mol Cell Biochem 380:259–265CrossRefPubMed
22.
23.
go back to reference Perbellini R, Greco S, Sarra-Ferraris G, Cardani R, Capogrossi MC, Meola G, Martelli F (2011) Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord 21:81–88CrossRefPubMed Perbellini R, Greco S, Sarra-Ferraris G, Cardani R, Capogrossi MC, Meola G, Martelli F (2011) Dysregulation and cellular mislocalization of specific miRNAs in myotonic dystrophy type 1. Neuromuscul Disord 21:81–88CrossRefPubMed
24.
go back to reference Cheng Q, Yi B, Wang A, Jiang X (2013) Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. Onco Targets Ther 6:1675–1684PubMedPubMedCentral Cheng Q, Yi B, Wang A, Jiang X (2013) Exploring and exploiting the fundamental role of microRNAs in tumor pathogenesis. Onco Targets Ther 6:1675–1684PubMedPubMedCentral
25.
go back to reference Pallante P, Battista S, Pierantoni GM, Fusco A (2014) Deregulation of microRNA expression in thyroid neoplasias. Nat Rev Endocrinol 10:88–101CrossRefPubMed Pallante P, Battista S, Pierantoni GM, Fusco A (2014) Deregulation of microRNA expression in thyroid neoplasias. Nat Rev Endocrinol 10:88–101CrossRefPubMed
26.
go back to reference Schuler S, Ponnath M, Engel J, Ortmann O (2013) Ovarian epithelial tumors and reproductive factors:a systematic review. Arch Gynecol Obstet 287:1187–1204CrossRefPubMed Schuler S, Ponnath M, Engel J, Ortmann O (2013) Ovarian epithelial tumors and reproductive factors:a systematic review. Arch Gynecol Obstet 287:1187–1204CrossRefPubMed
27.
go back to reference Anderson KN, Schwab RB, Martinez ME (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 144:1–10CrossRefPubMedPubMedCentral Anderson KN, Schwab RB, Martinez ME (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 144:1–10CrossRefPubMedPubMedCentral
29.
go back to reference Ørngreen MC, Arlien-Søborg P, Duno M, Hertz JM, Vissing J (2012) Endocrine function in 97 patients with myotonic dystrophy type 1. J Neurol 259:912–920CrossRefPubMed Ørngreen MC, Arlien-Søborg P, Duno M, Hertz JM, Vissing J (2012) Endocrine function in 97 patients with myotonic dystrophy type 1. J Neurol 259:912–920CrossRefPubMed
30.
go back to reference Srebnik N, Margalioth EJ, Rabinowitz R, Varshaver I, Altarescu G, Renbaum P, Levi-Lahad E, Weintraub A, Eldar-Geva T (2014) Ovarian reserve and PGD treatment outcome in women with myotonic dystrophy. Reprod Biomed Online 29:94–101CrossRefPubMed Srebnik N, Margalioth EJ, Rabinowitz R, Varshaver I, Altarescu G, Renbaum P, Levi-Lahad E, Weintraub A, Eldar-Geva T (2014) Ovarian reserve and PGD treatment outcome in women with myotonic dystrophy. Reprod Biomed Online 29:94–101CrossRefPubMed
Metadata
Title
Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors
Authors
Maria Laura Ester Bianchi
Emanuele Leoncini
Marcella Masciullo
Anna Modoni
Shahinaz M. Gadalla
Roberto Massa
Emanuele Rastelli
Chiara Terracciano
Giovanni Antonini
Elisabetta Bucci
Antonio Petrucci
Sandro Costanzi
Massimo Santoro
Stefania Boccia
Gabriella Silvestri
Publication date
01-03-2016
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 3/2016
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-8006-y

Other articles of this Issue 3/2016

Journal of Neurology 3/2016 Go to the issue